#ACR22 Abstr#1205. Are both mRNA vaccine Pfizer or Moderna equivocal in preventing breakthrough infection in fully vaccinated patients with SARDs? @zach_wallace_md showed comparable effectiveness between the two. We can promote whichever brands to our patients @RheumNow https://t.co/yhjxNE8pr2

Ab0374 #ACR22 BASDAI during pregnancy: 50 pregnant women w/ AS vs controls AUC for BASDAI in 1st trimester: 0.74, max value for morning stiffness severity (0.9) & duration (0.8) In 2nd and 3rd trimester: AUC for fatigue and back pain <0.5, morning stiffness remains 0.8 @RheumNow https://t.co/ZQyB37dDxX

Abs 0135 suggests that JAKi may successful tx for Inflammatory ocular pathology (IOP), including uveitis, epi/scleritis, & peripheral ulcerative keratitis, including after failure of cs/bDMARDs. #ACR22 @RheumNow https://t.co/9EDhtSzj1C https://t.co/0LqssF1P8H

Early AMPLE study proteomic analysis showed 3 potential biomarkers (ANGPT1, TNFRSF10C, and GIF) for predicting CV risk/RA tx response to ABA vs ADA in Abs 0244. Possible new markers for personalized medicine? Can't wait to see more! #ACR22 @RheumNow https://t.co/QRpjJWzNYH https://t.co/6t6SDbouII

The Navajo Nation has 1 rheumatologist - equitably they need 19 since #RA is 3 times more prevalent! - Dr. J Mandal #ACR22 @rheumnow https://t.co/QcAVJzd4YY https://t.co/zMuZMtl6KC

BIOBADASER 3.0 registry analysis shows risk of incident cancer in patients with rheumatic diseases and previous malignancy did not differ between TNFi or other b/tsDMARDs. Exciting, real-world data. Abs 0267 #ACR22 @RheumNow https://t.co/vZIN3U0QED https://t.co/EM1xXOv0Yd

Alternate-day GC in IgG4-RD reduced GC-related AEs (adjusted for cumulative GC doses) w/o increase in dz flares particularly when combined w/ immunosuppressants. Possible new tx strategy for clinic? Need more data re: long-term dz Abs 0128 #ACR22 @RheumNow https://t.co/a1c1ZDeOCK https://t.co/3deUugpcVW

CAR-T cells in #sle - talk of the town this year! reset the immune system? deep depletion CD19+ B cell and tissue plasmablasts. 5 pts with SLE - drug free remission at 8 months. Costs and risks still limiting use widely. year in review #ACR22 @rheumnow https://t.co/ophgPjCDuF

Data from - CARRA registry sJIA-Lung Disease cohort - Affects 1 in 20 pts - Interstitial lung disease (ILD) and pulmonary alveolar proteinosis (PAP). 13 pts - common features - tachypnea, clubbing, cough, finger and toe erythema #MAS in 56% pts. @RheumNow #ACR22 abst#0864 https://t.co/Q8fEzOkjJ7

Sode et al Mortality in GCA. Dominated by CV disease and higher than controls. Less cancer than controls @rheumnow #ACR22 Abstr#0467 https://t.co/TsfTWFRxJ2 https://t.co/lCZgVTpKUY